Hepatotoxicity induced by coxibs: how concerned should we be? - Wikidata - awgldk - TriplyDB

Hepatotoxicity induced by coxibs: how concerned should we be?

Hepatotoxicity induced by coxibs: how concerned should we be?

http://www.wikidata.org/entity/Q30244369

about

Genistein Exposure Interferes with Pharmacokinetics of Celecoxib in SD Male Rats by UPLC-MS/MS.Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials.Mutagenicity and teratogenicity studies of vitacoxib in rats and mice

P2860

Q48129186-5AECFA3F-3C05-4FA4-B2B4-B459B21B1907 Q55286744-96896B54-4160-4786-A669-530038146036 Q58785941-3FEDC6F5-4F0A-4043-BB3B-B63CA7468FC3

P2860

Hepatotoxicity induced by coxibs: how concerned should we be?

http://www.wikidata.org/entity/Q30244369

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Hepatotoxicity induced by coxibs: how concerned should we be?

@ast

Hepatotoxicity induced by coxibs: how concerned should we be?

@en

type

label

Hepatotoxicity induced by coxibs: how concerned should we be?

@ast

Hepatotoxicity induced by coxibs: how concerned should we be?

@en

prefLabel

Hepatotoxicity induced by coxibs: how concerned should we be?

@ast

Hepatotoxicity induced by coxibs: how concerned should we be?

@en

P1433

Q30244369-82482800-AEE5-475E-8968-AE4F044D9F13

P1476

Q30244369-C2DB723B-EFF6-4DB1-8A0C-0F21A867AA71

P2093

Q30244369-083BCFC2-F3EB-4BF0-A0DD-7AED006CB25E

Q30244369-17F35B1C-458F-407B-8C61-8A503C71580E

Q30244369-92F8D914-DFB6-42BE-BA05-E2C8146C87B2

Q30244369-9EFFCE48-27DC-4230-A8E4-178AC5086132

Q30244369-BB6AFF14-21A5-46BC-9E0B-1E1A04ACB02F

Q30244369-BD024A76-F072-422F-93C1-6BC73575C190

Q30244369-F4463BD8-F5A5-48FB-A059-E0C952A9302B

P2860

Q30244369-014EADBF-5698-4205-9D28-CB560A933825

Q30244369-05F3F1CB-2AD0-4FAF-85B4-A5AC3B9E406F

Q30244369-0BE69391-7485-4A1F-88FE-624F8D06A149

Q30244369-12466F87-8D42-4235-A1BA-4F484D4070D8

Q30244369-12C34229-9688-4651-A9D8-EF45B984B39D

Q30244369-2137D4A3-016F-4B60-BA4A-C0D977791660

Q30244369-2397EC36-D37F-4800-B2E2-343B156346EC

Q30244369-288E8BDD-9422-4263-8510-CB4DF36E6765

Q30244369-29972DB1-94E9-4682-AC29-E4714B6F0922

Q30244369-2F05BF6A-DBC6-4106-AB04-20EE7E59D2E7

P304

Q30244369-C1B6FEAA-29E4-4409-812D-3D0B19FE0A6E

P31

Q30244369-1DBC1FB3-3C54-4AAC-A4DC-8E323F5E5327

P356

Q30244369-8DB8F6B6-2999-4050-9C61-52F03DA35191

P407

Q30244369-09EFF772-F6AA-4A12-8BA7-C9B386B229AC

P433

Q30244369-8877BAD8-EF3A-4C65-BC71-F2238222668C

P478

Q30244369-A18864E3-58A9-48A6-84BF-D170640E4A17

P50

Q30244369-99E03390-01DB-4B4B-A0C9-51CA3200BC78

Q30244369-B73E12B5-2151-4A30-A42D-7FE697B94E45

P577

Q30244369-4E715CEC-5AE2-43EB-B8C9-622A67854279

P698

Q30244369-5BB312D9-381C-43E5-9519-327DE7A43BF6

P921

Q30244369-7D774D19-CBE3-4551-9573-A018133BEC92

P356

14740338.2016.1225719

P1433

Expert Opinion on Drug Safety

P1476

Hepatotoxicity induced by coxibs: how concerned should we be?

@en

P2093

Fernando Bessone

http://www.w3.org/2001/XMLSchema#string

Inmaculada Medina-Cáliz

http://www.w3.org/2001/XMLSchema#string

M Isabel Lucena

http://www.w3.org/2001/XMLSchema#string

Manuel Mendizabal

http://www.w3.org/2001/XMLSchema#string

Marcelo Gabriel Roma

http://www.w3.org/2001/XMLSchema#string

Nelia Hernandez

http://www.w3.org/2001/XMLSchema#string

Raúl J Andrade

http://www.w3.org/2001/XMLSchema#string

P2860

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs

Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes

The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthrit

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

Anti-inflammatory drugs in the 21st century

Drug Points: Cholestatic hepatitis in association with celecoxib

P304

1463-1475

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2016.1225719

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Mercedes Robles-Diaz

P577

2016-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27537326

http://www.w3.org/2001/XMLSchema#string

P921